{
    "root": "845065f7-20e0-41bb-baee-00004b71c5d2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ACTIMMUNE",
    "value": "20250417",
    "ingredients": [
        {
            "name": "INTERFERON GAMMA-1B",
            "code": "21K6M2I7AG",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5939"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "SODIUM SUCCINATE HEXAHYDRATE",
            "code": "U16QOD6C4E",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_63686"
        },
        {
            "name": "SUCCINIC ACID",
            "code": "AB6MNQ6J6L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15741"
        },
        {
            "name": "POLYSORBATE 20",
            "code": "7T1F30V5YH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53424"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "actimmune indicated reducing frequency severity serious infections associated chronic granulomatous disease ( cgd ) . actimmune indicated delaying time disease progression patients severe , malignant osteopetrosis ( smo ) .",
        "doid_entities": [
            {
                "text": "chronic granulomatous disease (DOID:3265)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3265"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "osteopetrosis (DOID:13533)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13533"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "chronic granulomatous disease",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_379"
            }
        ]
    },
    "contraindications": {
        "text": "subcutaneous ( 2.1 ) recommended dose 50 mcg/m 2 patients whose body surface area greater 0.5 2 1.5 mcg/kg/dose patients whose body surface area equal less 0.5 2 three times weekly . ( 2.1 ) monitor hematology , blood chemistries urinalysis prior beginning treatment 3-month intervals . ( 2.1 ) severe occur , reduce dose 50 percent discontinue therapy reaction abates . ( 2.3 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "actimmune ( interferon gamma-1b ) sterile , clear , colorless solution filled single-dose vial subcutaneous injection . vial permits extraction 0.5 ml actimmune additional volume facilitate solution withdrawal . 0.5 ml actimmune contains : 100 mcg ( 2 million international units ) interferon gamma-1b . ndc number size 75987-111-10 one vial 75987-111-11 cartons 12 vials",
    "adverseReactions": "actimmune contraindicated patients develop known hypersensitivity interferon gamma , e. coli derived products , component product .",
    "indications_original": "ACTIMMUNE is indicated for reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease (CGD).\n                     ACTIMMUNE is indicated for delaying time to disease progression in patients with severe, malignant osteopetrosis (SMO).",
    "contraindications_original": "For subcutaneous use only ( 2.1 ) The recommended dose is 50 mcg/m 2 for patients whose body surface area is greater than 0.5 m 2 and 1.5 mcg/kg/dose for patients whose body surface area is equal to or less than 0.5 m 2 three times weekly. ( 2.1 ) Monitor hematology, blood chemistries and urinalysis prior to the beginning of treatment and at 3-month intervals. ( 2.1 ) If severe reactions occur, reduce dose by 50 percent or discontinue therapy until the adverse reaction abates. ( 2.3 )",
    "warningsAndPrecautions_original": "ACTIMMUNE (interferon gamma-1b) is a sterile, clear, colorless solution filled in a single-dose vial for subcutaneous injection. Each vial permits the extraction of up to 0.5 mL of ACTIMMUNE with additional volume to facilitate solution withdrawal. Each 0.5 mL of ACTIMMUNE contains: 100 mcg (2 million International Units) of interferon gamma-1b.\n                        \n                           \n                           \n                           \n                              \n                                 NDC Number\n                                 Size\n                              \n                           \n                           \n                              \n                                 75987-111-10\n                                 One vial\n                              \n                              \n                                 75987-111-11\n                                 Cartons of 12 vials",
    "adverseReactions_original": "ACTIMMUNE is contraindicated in patients who develop or have known hypersensitivity to interferon gamma, E. coli derived products, or any component of the product.",
    "drug": [
        {
            "name": "ACTIMMUNE",
            "drugbank_id": "https://go.drugbank.com/drugs/DB12860"
        }
    ]
}